Skip to content
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Loading stock detail

Preparing the latest stock view…

We're pulling the screening verdict, quote snapshot, and company context now.

Is Syngene International Ltd. Shariah Compliant? | BarakFi | BarakFi
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Home›Screener›SYNGENE
SYNGENE logo
SYNGENENSE

Syngene International Ltd.

Healthcare · Mid Cap · India
₹442
▼ ₹20.4 (-4.41%) today
Day Range: ₹436.05 – ₹464.15
Volume: 9.4 L · as of 29 May 2026, 6:02 pm
Shariah Status
Shariah Compliant
Report Credit
Opening this stock page uses 1 of your 50 monthly report credits.
Last screened 29 May 2026, 7:39 pm IST.
Methodology
AAOIFI aligned · 2026.04.2
See Full Breakdown
Shariah Compliant
Compliance
Market Data
About
Similar Stocks
Add to Watchlist
Share
Shariah Compliance Breakdown
Debt Ratio
Interest-bearing debt compared to methodology denominator (AAOIFI: total assets). Must stay below 30%.
Disclaimer:The information on this page is for educational purposes only and does not constitute a religious ruling (fatwa) or financial advice. Shariah compliance status is derived from publicly available financial data and BarakFi's methodology mapping. Individual scholars may reach different conclusions. Always consult a qualified Islamic finance scholar and a licensed financial advisor before making investment decisions.
BarakFi
Shariah-compliant stock research for Indian equities. Educational only.
Product
ScreenerWatchlistCompare
Learn
MethodologyAbout
Legal
PrivacyDisclaimer
© 2026 BarakFi · Educational screening · Not a religious ruling or financial adviceMade in India
Threshold: 30%
0.1%
Pass
Interest Income
Interest and treasury-based income as a share of business income. Must stay below 5%.
Threshold: 5%
0.0%
Pass
Non-permissible Income
Non-halal income compared to total business income. Must stay below 5%.
Threshold: 5%
Not detected
Pass
Accounts Receivable
Receivables compared to methodology denominator (AAOIFI: total assets). Must stay below 49%.
Threshold: 49%
7.2%
Pass
Business Activity
Core business lines should avoid prohibited sectors and interest-driven revenue dependence.
Allowed
Pass
Cash & Interest-bearing Assets
Cash, equivalents, and interest-bearing balances compared to total assets. Must stay below 30%.
Threshold: 30%
9.7%
Pass
Why Shariah Compliant
Syngene International Ltd. currently screens as Shariah compliant on BarakFi. All required checks pass with current data.
Market Data
Current Price
₹442
Day Range
₹436.05 – ₹464.15
52-Week Range
₹380 – ₹728.6
Volume
9.4 L
Market Cap
₹17,762 Cr
P/E Ratio
49.6×
About Syngene International Ltd.

Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka and currently employs 6,847 full-time employees. The company went IPO on 2015-08-11. The firm is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. The company serves the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

BarakFi combines that company context with filing-driven screening ratios, market-cap evidence, and live quote snapshots so you can review the stock through a Shariah-screening lens without losing the underlying business picture.

Index and universe context: Nifty 500 • Nifty MIDCAP 100.

HealthcareMid CapIndiaNSENifty 500Nifty MIDCAP 100
Other Stocks in Healthcare
SUNPHARMA
Sun Pharmaceutical Industries Ltd.
Compliant
DIVISLAB
Divi's Laboratories Ltd.
Requires Review
TORNTPHARM
Torrent Pharmaceuticals Ltd.
Not Compliant
APOLLOHOSP
Apollo Hospitals Enterprise Ltd.
Compliant
CIPLA
Cipla Ltd.
Compliant
Key Compliance Ratios
Debt Ratio0.1%
Interest Income0.0%
Non-permissible IncomeNot detected
Receivables Ratio7.2%
Overall StatusCompliant
Stock Information
TickerSYNGENE
ExchangeNSE
SectorHealthcare
CountryIndia
Market Cap₹17,762 Cr
36M Avg MCap₹28,056 Cr
Cap SizeMid Cap
About this Screening
This page uses an AAOIFI-aligned methodology version 2026.04.2, checking debt, interest income, non-permissible income, receivables, and balance-sheet context from the current filings dataset.

This is educational only — not a religious ruling or financial advice. Read the full methodology for threshold context and update cadence.

Read full methodology →
Track this stock
Add SYNGENE to your watchlist so you can revisit its status after the next fundamentals sync.
Open Watchlist